In accordance with the Act on Evaluation and Registration of Chemical Substances, we, as the representative company of the consultative body, completed the registration of the substance Ammonium metavanadate in December 2021. The results of the first hazard assessment conducted during that period have been notified as follows.
1. Results of the first hazard assessment
Based on the results, the classification will be added and toxic substances will be designated as follows, and we will provide you with the necessary information for safety management.
■ Classification of evaluation results:
① Acute toxicity - oral (category 3)
② Acute toxicity - inhalation (category 4)
③ Severe eye damage/eye irritation (Category 2)
④ Skin hypersensitivity (category 1)
⑤ Aquatic environmental hazards - chronic (category 2)
⑥ Specific target organ toxicity - repeated exposure (category 1)
■ Matters required for safety management
① Since acute oral toxicity and repeated exposure toxicity meet the criteria for designation as a toxic substance, this substance is expected to be designated as a toxic substance and the relevant information will be communicated to those handling this substance.
② Comply with the regulations of the Chemical Substances Control Act, including the hazardous chemical substance business license.
2. Secondary hazard assessment
This substance has been ordered to submit secondary hazard assessment data from the National Institute of Chemical Safety.
■ Submission of materials
① Re-examination of data on genotoxicity, reproductive toxicity, and carcinogenicity and classification labeling accordingly.
② Data on the risk of harm reflected in the data
■ Response measures
Data will be secured and submitted by the deadline (July 2, 2026).